To assess the clinical efficacy of the investigational SARS-CoV-2 Recombinant Protein vaccine (with adjuvant) in SARS-CoV-2 naïve adults for the prevention of symptomatic COVID-19 occurring = 14 days after the second injection.

To assess the clinical efficacy of the investigational SARS-CoV-2 Recombinant Protein vaccine (with adjuvant) in SARS-CoV-2 naïve adults for the prevention of symptomatic COVID-19 occurring = 14 days after the second injection.